Biocon Limited's wholly owned subsidiary Biocon Pharma Limited has received approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application ...

Biocon Pharma, a subsidiary of Biocon Ltd, has secured approval from the US FDA for its generic Liraglutide injection ...

Biocon said its arm, Biocon Pharma, has received approval from the U.S. Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Liraglutide injection (gVictoza), 18 mg ...

Biocon’s subsidiary Biocon Pharma has received the Food and Drug Administration’s permission for norepinephrine bitartrate injection (4 mg/4 ml, 1 mg/ml) in a single-dose vial, the company said in a ...

Bengaluru: Biocon is doubling down on its internal operations with fresh capital support to two key subsidiaries. The company completed the acquisition of preference shares in both entities on March 3 ...

Biocon Biologics is among the leading global suppliers of biosimilar insulins and has been expanding its portfolio ...

Biocon said its wholly owned subsidiary Biocon Pharma has received US FDA approval for its ANDA for Liraglutide Injection (gVictoza) 18 mg/3 mL prefilled pens used to treat Type 2 diabetes, following ...

Biocon Ltd has completed the acquisition of OCRPS in its wholly owned subsidiaries. It bought 11.53 crore OCRPS of Biocon Biosphere Ltd for ₹115.34 crore (₹20 crore in cash, ₹95.34 crore via earlier ...

Sitagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes. The Food and Drug Administration has given Biocon Ltd.’s wholly owned ...

Biocon Ltd has finalised the purchase of Optionally Convertible Redeemable Non-Cumulative Preference Shares (OCRPS) from its subsidiaries for ₹315 crore.